<?xml version="1.0" encoding="UTF-8"?>
<svg height="870.031005859375" width="672.0029907226562" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <path d=" M 0.05999799817800522 826.072021484375 L 22.619997024536133 826.072021484375 L 22.619997024536133 826.35546875 L 0.05999799817800522 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 837.4110107421875 L 33.959449768066406 837.4110107421875 L 33.959449768066406 860.031005859375 L 33.67599868774414 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 837.4110107421875 L 628.2703857421875 837.4110107421875 L 628.2703857421875 860.031005859375 L 627.9869995117188 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 826.072021484375 L 662.0029907226562 826.072021484375 L 662.0029907226562 826.35546875 L 639.3259887695312 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 33.731998443603516 L 662.0029907226562 33.731998443603516 L 662.0029907226562 34.015480041503906 L 639.3259887695312 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 0.0 L 628.2703857421875 0.0 L 628.2703857421875 22.677000045776367 L 627.9869995117188 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 0.0 L 33.959449768066406 0.0 L 33.959449768066406 22.677000045776367 L 33.67599868774414 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 0.05999799817800522 33.731998443603516 L 22.619997024536133 33.731998443603516 L 22.619997024536133 34.015480041503906 L 0.05999799817800522 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 85.03900146484375 630.594970703125 L 566.248046875 630.594970703125 C 579.416015625 630.636962890625 590.1820068359375 619.8469848632812 590.115966796875 606.6709594726562 L 590.115966796875 418.33697509765625 L 85.03900146484375 418.33697509765625" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 85.03900146484375 630.594970703125 L 566.248046875 630.594970703125 L 566.248046875 630.3679809570312 L 85.26599884033203 630.3679809570312" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 566.2490234375 630.594970703125 L 569.9910278320312 630.3119506835938 C 580.1680297851562 628.719970703125 588.2870483398438 620.6019897460938 589.8330078125 610.4119873046875 L 590.1170043945312 606.6709594726562 L 589.8900146484375 606.6709594726562 L 589.6069946289062 610.4119873046875 C 587.9960327148438 620.6119995117188 580.0670166015625 628.365966796875 569.9340209960938 630.0849609375 L 566.2490234375 630.3679809570312" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 590.1160278320312 606.6710205078125 L 590.1160278320312 418.3370361328125 L 589.8890380859375 418.62103271484375 L 589.8890380859375 606.6710205078125" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 590.1160278320312 418.3370056152344 L 85.03903198242188 418.3370056152344 L 85.26602172851562 418.6199951171875 L 589.8890380859375 418.6199951171875" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 85.03900146484375 418.3370056152344 L 85.03900146484375 630.594970703125 L 85.26599884033203 630.3680419921875 L 85.26599884033203 418.6199951171875" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="85.039,98.312,109.93,117.185,129.222,136.895,147.47500000000002,154.214,166.251,173.50400000000002,180.181,191.799,204.254,211.928,217.728,228.31,239.929,250.929,262.548,275.003,280.803,292.422,300.711,307.478,319.514,331.97,344.425,356.462,364.135,376.59,388.627,394.427,400.228,411.846,417.644,424.307,436.344,444.635,456.672,473.053,480.838,493.291,499.944,507.199,518.817,530.436,538.109,550.146" y="81.077" svg_rhmargin="558.435" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:19.93px;font-style:NORMAL;font-weight:normal;">Safety of antivascular endothelial growth factor</text>
  <text x="85.039,96.66,109.117,127.373,133.175,145.632,151.434,162.437,170.112,178.405,190.183,197.858,203.661,215.7,228.153,234.812,240.614,253.067,259.76,267.436,279.893,291.928,298.547,310.586,322.206,334.664,340.466,352.194,360.483,367.104,378.724,391.182,398.857,410.896,419.189,424.991,437.03,445.31899999999996,451.966,462.969,475.007,487.046,505.302,517.341,529.798,537.469,544.144,549.947" y="101.03200000000004" svg_rhmargin="562.4" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:19.93px;font-style:NORMAL;font-weight:normal;">administration in the ocular anterior segment in</text>
  <text x="85.039,97.499,105.176,117.217,125.512,136.098,148.139,153.943,166.402,184.653,191.293,202.915,215.375,227.828,234.505,246.964,259.005,271.046,281.632,293.255,304.26,315.882,328.341,334.145,345.768,354.05699999999996,360.724,372.765,378.569,390.191,402.651,414.273,426.314,444.572,456.188,462.895,470.572,478.867,490.908,502.53,510.207,528.465,540.506,552.965" y="120.93200000000002" svg_rhmargin="560.636" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:19.93px;font-style:NORMAL;font-weight:normal;">pterygium and neovascular glaucoma treatment</text>
  <text x="85.039,95.319,103.447,111.91,117.376,126.492,140.757,149.873,155.339,159.323,168.441,173.746,179.881,188.997,197.125,201.109,210.225,223.168,228.5,237.617,246.908,256.536,261.832,276.097,285.213,290.679,299.795,306.265,315.382,324.673,333.789,337.773,345.901,354.364,358.347" y="142.02200000000005" svg_rhmargin="366.811" style="fill:#171615;font-family:DPNDFK+AdvOT34fe1490.B;font-size:15.94px;font-style:NORMAL;font-weight:normal;">Systematic review and meta-analysis</text>
  <text x="85.039,91.577,97.132,98.984,102.791,105.835,111.61,117.164,122.938,126.425,133.716,139.271,144.606,150.16,155.935,158.75900000000001,162.198,170.796,177.878,180.702,184.194,191.161,193.013,196.82,201.831,207.386,212.721,218.276,221.782,227.556,229.408,234.742,240.297,243.121,246.613,255.212,262.294,265.118,268.554,276.284,281.839,285.335,291.318,293.17,298.505,304.279,307.103,310.619,319.218,326.3,329.124,332.616,339.154,344.708,351.79,354.61400000000003,358.071,364.389,370.164,375.718,381.492,385.3,387.152,392.706,398.041,403.596,407.053,413.371,418.706,424.261,430.035,432.85900000000004,436.363,444.962,452.044,454.868,458.303,464.841,470.396,472.247,476.055,480.846,486.62,492.175,495.664,501.647,507.202,512.976,518.531,521.3549999999999,524.861,533.459,540.541,543.365,546.857,553.395,558.95" y="159.82399999999996" svg_rhmargin="566.032" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:10.46px;font-style:NORMAL;font-weight:normal;">Shi-tong Huang, MD, Bi-shan Tian, MD, Ou Xiao, MD, PhD, Yong-juan Yang, MD, Shi-you Zhou, MD, PhD</text>
  <text x="565.965" y="153.19100000000003" svg_rhmargin="570.045" style="fill:#171615;font-family:DPNDFM+AdvOTb0c9bf5d+22;font-size:6.97px;font-style:NORMAL;font-weight:normal;">∗</text>
  <text x="91.276,97.915,104.052,109.607,113.09,117.155,123.045,128.935" y="181.59400000000005" svg_rhmargin="132.418" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Abstract</text>
  <text svg_rhmargin="152.86" x="91.276,98.329,104.219,110.109,115.832,121.969,126.034,132.171,137.932,143.822,149.959,152.86" y="191.572" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Background: </text>
  <text x="154.318,159.922,164.683,167.292,168.879,172.143,177.37,182.598,189.224,193.98499999999999,195.759,200.332,205.282,209.854,214.616,217.225,221.51999999999998,223.311,228.072,232.645,236.94,238.675,243.804,248.376,252.949,257.71000000000004,259.48,266.106,267.693,272.822,277.395,278.982,283.088,284.878,289.639,293.934,298.507,303.636,305.457,307.044,311.805,313.564,318.514,323.086,327.847,329.435,334.007,336.80400000000003,338.565,343.694,345.281,349.576,354.148,358.721,363.016,367.589,371.884,374.305,376.094,381.223,385.984,388.59299999999996,390.38,391.967,394.576,398.87100000000004,400.641,404.936,409.509,411.751,416.323,418.933,423.039,424.849,427.09,432.039,434.836,436.584,439.193,441.99,446.563,451.136,453.745,455.332,460.093,465.04200000000003,466.857,471.429,476.19,478.8,483.372,486.17,487.757,492.706,495.50300000000004,497.243,501.538,506.111,511.06,518.431,523.004,527.765,530.374,532.165,537.294,538.881,543.176,548.125,550.923,556.052,560.624,563.422,567.717,570.138,571.962,574.571,579.333" y="191.572" svg_rhmargin="583.906" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Anti-VEGF agents has been widely used in ocular diseases, but its safety for treating anterior segment disorders, the</text>
  <text x="91.275,95.848,100.797,105.558,110.131,111.718,116.479,120.774,122.361,127.311,132.072,136.367,139.349,143.922,146.719,151.292,154.315,158.888,163.838,168.599,171.208,174.005,178.955,183.061,187.634,190.432,194.727,196.314,200.886,202.473" y="202.51300000000003" svg_rhmargin="204.894" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">conclusions are controversial.</text>
  <text svg_rhmargin="136.323" x="91.276,100.242,106.22,109.703,115.593,121.73,127.867,133.422,136.323" y="216.74300000000005" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Methods: </text>
  <text x="140.598,146.202,150.775,154.882,159.455,162.252,166.825,168.41199999999998,173.139,180.509,185.082,186.669,191.618,194.415,199.16,204.289,208.862,211.471,216.044,221.172,225.745,230.04,234.613,238.908,241.32899999999998,246.1,247.687,252.449,257.021,258.608,263.37,268.498,270.085,274.846,279.795,284.537,290.787,296.014,302.264,307.213,313.185,318.788,323.55,325.971,330.684,338.054,343.282,349.352,354.113,356.068,362.317,367.545,369.966,374.733,379.306,384.067,389.196,393.951,399.179,406.549,412.52,418.124,423.728,428.956,431.377,436.13,442.756,447.328,450.126,454.69899999999996,459.43,463.725,468.298,472.871,475.668,480.241,485.002,489.575,494.704,497.125,501.836,507.439,512.012,514.254,518.827,521.436,525.542,530.295,535.423,539.996,542.605,547.178,551.894,554.136,556.933,561.883,569.253,574.004,578.954" y="216.74300000000005" svg_rhmargin="583.903" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Several major databases, including CENTRAL, MEDLINE, and EMBASE, were searched. Safety data from 18</text>
  <text x="91.276,94.073,98.646,103.407,108.536,113.485,120.856,122.443,126.549,131.122,136.251,139.236,143.809,148.759,153.52,156.129,158.926,163.876,165.463,167.05,171.623,176.75199999999998,179.77,182.38,185.177,186.764,191.337,192.924,197.219,200.236,202.379,208.35,214.6,219.549,223.844,225.987,228.978,235.604,240.177,242.975,247.548,250.521,255.282,259.577,264.15,269.279,272.29,274.899,279.848,282.834,287.407,292.357,299.727,304.856,309.428,312.226,316.799,319.797,324.37,329.131,331.74,333.327,336.591,341.818,347.046,353.672,358.43300000000005,361.465,364.075,366.872,371.445,376.018,378.627,385.997,390.57,395.331,397.94,400.922,402.509,407.27000000000004,410.277,412.886,417.647,422.21999999999997,425.187,430.136,434.709,439.47,441.057,445.63,448.427,451.435,456.008,460.769,463.378,467.951,470.748,472.335,477.285,480.08200000000005,483.069,487.364,491.937,496.886,504.256,508.829,513.59,516.1990000000001,519.181,520.768,525.529,528.535,533.664,536.273,540.846,543.644,547.75,552.7,554.287,559.048,566.418,569.41,573.983,578.744" y="227.68499999999995" svg_rhmargin="583.873" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">randomized controlled trials (RCTs) were used to compare anti-VEGF treatment in the ocular anterior segment in pterygium and</text>
  <text x="91.276,96.037,100.61,105.559,109.666,114.238,118.533,123.106,127.867,129.454,134.027,136.82399999999998,138.669,143.618,145.205,149.778,154.539,159.112,164.061,171.432,176.005,177.843,180.452,183.249,187.822,192.395,195.004,202.374,206.947,211.708,214.317,216.166,222.792,224.379,226.988,231.749,233.57,238.699,240.286,244.859,249.431,254.004,259.133,264.082,266.969,271.264,276.025,280.598,287.968,289.864,292.473,295.271,299.844,304.416,307.026,314.396,318.969,323.73,326.339,328.187,330.428,335.378,338.175,339.979,344.551,348.658,353.231,355.058,360.187,361.774,366.069,370.641,375.214,379.509,384.082,388.377,390.798,392.644,398.248,400.071,407.441,412.014,414.623,419.196,422.46,427.032,431.793,436.366,437.953,442.06,446.355,447.942,452.237,454.097,456.339,461.288,464.08500000000004,465.889,470.462,475.59,479.697,484.27,487.067,491.362,495.935,497.806,502.379,506.485,511.058,515.819,518.429,522.7239999999999,524.564,531.19,535.763,540.058,541.912,547.041,551.614,554.411,556.653,561.602,564.4,571.77,576.343,581.472" y="238.62699999999995" svg_rhmargin="583.893" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">neovascular glaucoma treatment with placebo/sham treatment for eye diseases. A meta-analysis for adverse events was performed.</text>
  <text svg_rhmargin="129.676" x="91.276,97.994,103.972,109.527,115.417,117.737,121.22,126.775,129.67600000000002" y="252.85699999999997" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Results: </text>
  <text x="131.981,137.208,138.795,143.745,148.506,151.115,155.688,160.261,165.022,167.697,173.668,179.918,184.86700000000002,187.595,191.89,194.5,199.261,204.389,205.976,210.549,214.844,217.529,224.155,225.742,228.351,233.112,235.84,240.789,245.738,250.687,253.357,257.93,262.036,266.609,270.904,273.652,280.278,284.851,287.649,292.222,294.911,296.498,301.26,305.832,307.419,312.18,317.309,321.882,327.011,329.719,331.306,336.067,338.791,341.4,346.161,350.734,353.417,360.788,365.361,367.97,372.543,375.806,380.379,385.14,389.713,391.3,395.407,399.701,401.288,405.583,408.004,410.732,416.336,417.923,422.872,427.633" y="252.85699999999997" svg_rhmargin="429.22" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Eighteen RCT studies with 955 eyes were included in the meta-analysis. Signi</text>
  <text x="429.223" y="252.85699999999997" svg_rhmargin="433.141" style="fill:#171615;font-family:DPNDFO+AdvOT6e5d2ec0+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="433.135,437.708,442.281,447.042,449.65099999999995,452.41,457.538,459.126,461.367,463.609,468.181,470.979,475.552,480.313,484.886,489.459,492.15,493.737,498.49800000000005,501.221,505.794,510.744,515.505,517.092,521.853,526.614,531.187,533.796,535.383,539.49,544.062,545.649,548.331,553.46,555.047,559.342,564.291,567.089,572.217,576.79,579.588" y="252.85699999999997" svg_rhmargin="583.883" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cant difference in conjunctival disorders</text>
  <text x="91.275,93.418,100.044,106.016,108.43700000000001,110.777,115.726,118.147,123.096,128.046,130.46699999999998,132.773,137.722,142.672,150.607,152.955,159.205,161.159,163.57999999999998,165.937,170.887,173.308,178.257" y="263.798" svg_rhmargin="183.206" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(OR: 1.62; 95% CI, 1.01</text>
  <text x="183.232" y="263.798" svg_rhmargin="187.715" style="fill:#171615;font-family:DPNDFP+AdvOT6e5d2ec0+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="207.4" x="187.71,192.66,195.081,200.03,204.979,207.4" y="263.798" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">2.59; </text>
  <text svg_rhmargin="215.311" x="209.707,215.311" y="263.798" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:8.97px;font-style:NORMAL;font-weight:normal;">P </text>
  <text x="216.453" y="263.798" svg_rhmargin="222.523" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">=</text>
  <text x="223.653,226.074,231.024,235.973,238.116,240.434,247.06,251.633,255.928,258.235,262.996,267.945,270.554,275.127,280.25600000000003,282.612,287.185,294.555,299.505,304.266,309.21500000000003,311.525,314.134,318.895,323.46799999999996,325.811,327.398,332.159,336.732,338.319,343.08,348.209,352.782,357.911,360.279,364.574,367.183,371.944,377.073,378.66,383.233,387.528,389.949,392.31,397.438,402.199,404.808,407.106,411.867,416.816,419.42499999999995,421.789,423.376,428.137,430.463,435.412,439.985,444.746,446.333,450.906,453.70300000000003,456.03,457.617,462.379,464.988,469.937,471.524,476.097,478.895,483.467,488.228,492.801,497.37399999999997,499.739,501.882,506.832,511.96,517.089,521.384,523.72,526.517,531.09,533.699,535.286,540.2349999999999,542.541,544.684,551.31,557.281,559.424,561.845,564.197,569.147,571.568,576.517,581.466" y="263.798" svg_rhmargin="583.887" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">.05) was noted among the included studies, but not in ocular intolerance (odds ratio [OR]: 0.75;</text>
  <text x="91.275,96.224,101.174,109.10900000000001,112.194,118.444,120.398,122.819,125.97,130.919,133.34,138.29" y="274.74" svg_rhmargin="143.239" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">95% CI, 0.34</text>
  <text x="143.262" y="274.74" svg_rhmargin="147.745" style="fill:#171615;font-family:DPNDFP+AdvOT6e5d2ec0+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="167.431" x="147.741,152.691,155.111,160.061,165.01,167.43099999999998" y="274.74" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1.62; </text>
  <text svg_rhmargin="176.136" x="170.532,176.13600000000002" y="274.74" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:8.97px;font-style:NORMAL;font-weight:normal;">P </text>
  <text x="177.278" y="274.74" svg_rhmargin="183.348" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">=</text>
  <text x="184.478,186.899,191.848,196.798,198.941,201.362,204.49,209.063,214.012,216.809,221.571,226.143,230.716,232.303,235.387,240.515,242.102,246.397,251.347,254.144,259.273,263.846,266.643,270.938,274.107,276.25,282.876,288.847,291.268,294.402,299.351,301.772,306.722,311.671,314.092,317.192,322.141,327.091,335.026,338.167,344.417,346.372,348.793,351.943,356.893,359.314,364.263" y="274.74" svg_rhmargin="369.212" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">.46), corneal disorders (OR: 0.71; 95% CI, 0.37</text>
  <text x="369.184" y="274.74" svg_rhmargin="373.667" style="fill:#171615;font-family:DPNDFP+AdvOT6e5d2ec0+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="393.352" x="373.662,378.612,381.033,385.982,390.931,393.352" y="274.74" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1.37; </text>
  <text x="396.509" y="274.74" svg_rhmargin="402.113" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:8.97px;font-style:NORMAL;font-weight:normal;">P</text>
  <text x="403.199" y="274.74" svg_rhmargin="409.269" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">=</text>
  <text x="410.399,412.82,417.769,422.719,424.862,427.283,430.411,435.36,438.15700000000004,441.296,443.905,448.666,453.239,456.376,460.671,465.432,470.561,475.511,478.308,483.257,488.019,493.148,496.287,500.86,505.621,510.194,511.781,515.888,520.182,521.769,526.064,529.168,534.118,536.36,539.486,544.059,549.008,553.769,555.356,560.117,564.879,569.451,572.061,573.648,577.754,582.327" y="274.74" svg_rhmargin="583.914" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">.31), or the subgroup analysis of conjunctival</text>
  <text x="91.273,96.402,97.989,102.284,107.233,110.031,115.159,119.732,122.53,126.825" y="285.73900000000003" svg_rhmargin="129.246" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">disorders.</text>
  <text svg_rhmargin="152.902" x="91.276,98.497,104.634,110.524,116.414,118.733,124.623,130.178,132.497,138.556,144.446,150.001,152.90200000000002" y="299.912" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Conclusions: </text>
  <text x="155.225,160.175,164.936,169.50900000000001,172.232,176.805,181.934,189.304,190.891,195.652,197.24,201.534,204.144,206.941,211.514,214.123,215.71,220.66,225.421,228.187,233.136,235.378,238.051,242.624,247.385,249.995,251.582,254.845,260.073,265.3,271.926,276.687,279.436,284.009,288.958,293.531,298.292,300.902,305.197,307.952,309.539,314.3,317.023,319.632,324.393,328.96599999999995,331.65,336.599,341.172,345.933,347.52,352.093,354.89000000000004,357.614,362.187,366.948,369.557,374.13,376.928,378.515,383.464,386.261,389.022,393.316,397.889,402.839,410.209,414.782,419.543,422.152,424.85,427.092,432.041,434.838,437.549,442.678,447.251,449.86,451.447,456.02,460.781,463.39,467.685,470.43,477.056,478.643,481.253,486.014,488.741,493.87,496.479,501.052,503.849,507.956,512.905,514.492,519.253,526.623,529.389,533.962,538.723,543.852,546.567,551.516,553.103,557.676,562.437,567.01,571.959,579.329" y="299.912" svg_rhmargin="583.902" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">The administration of anti-VEGF agents in the ocular anterior segment for patients with pterygium and glaucoma</text>
  <text x="91.276,97.902,102.475,106.77,109.53,112.139,117.089,118.676,123.249,126.046,130.619,135.748,137.335,141.90800000000002,144.679,146.266,151.027,153.807,156.416,161.365,162.952,167.525,170.323,174.895,179.657,184.229,188.80200000000002,191.563,196.136,200.897,206.02599999999998,208.797,213.37,218.319,221.117,225.878,230.451,235.024,237.445,240.261,245.389,250.151,252.76000000000002,255.511,262.137,266.71,271.005,273.822,276.431,281.192,285.765,288.505,291.302,292.889,297.184,301.66700000000003,304.435,306.677,311.25,315.822,318.432,323.381,326.178,328.982,333.932,336.17400000000004,338.904,343.476,348.426,353.187,354.774,359.535,364.296,368.869,371.478,373.065,377.172,381.745,383.332,386.127,391.256,392.843,397.138,402.087,404.885,410.013,414.586,417.384,421.679,424.09999999999997,426.888,431.837,436.599,441.17199999999997,443.952,448.713,453.286,457.859,459.446,461.033,465.794,470.743,473.488,478.437,480.67900000000003,483.465,488.038,492.988,495.785,500.546,505.119,509.692,511.279,514.022,518.594,523.723,525.31,527.919,532.681,537.253,538.84,540.427,545.189,552.559,555.349,562.719,567.292,571.398,574.17,579.299" y="310.853" svg_rhmargin="583.872" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">was tolerable in tolerance and cornea, but was the risk factor of conjunctival disorders. The healing of corneal epithelium may be</text>
  <text x="91.276,96.404,100.977,102.564,107.137,111.244,115.817,120.946,123.25,124.837,129.598,131.924,137.052,141.625,144.234,145.821,150.394,155.155,157.764,162.059,164.408,171.034,172.621,175.23,179.99099999999999,182.322,187.451,190.248,191.836,199.206,203.779,206.576,210.682,213.049,217.622,222.571,225.369,230.13,234.703,239.275,240.862,243.151,247.724,252.853,254.44,257.049,261.81,266.383,267.97,269.557,274.13,275.717,278.073,283.202,287.775,290.017,294.589,299.162,301.771,306.06600000000003,308.403,312.976,315.217,317.826,322.399,325.196,327.565,332.138,336.899,339.508,341.095,344.359,349.586,354.813,361.439,366.20000000000005,368.496,373.069,378.197,383.326,384.913,386.5,391.073,395.646,398.255,399.842,404.792,409.553,411.974,414.359,420.608,425.557,432.184,436.756,440.863,445.436,448.233,450.654,452.965,458.093,462.855,467.428,469.803,472.412,477.361,479.667,482.276,487.038,491.611,493.953,495.54,497.127,504.498,506.085,508.694,513.267,518.3960000000001,520.711,525.284,529.391,530.978,536.107,540.679,545.44,550.013,554.586,557.0070000000001,559.375,561.617,566.378,569.175,571.784,576.545,581.118" y="321.852" svg_rhmargin="583.915" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">delayed in patients with primary corneal epithelial defects after anti-VEGF application. However, due to the limited evidence, further</text>
  <text x="91.276,94.073,98.646,102.941,107.514,112.087,114.884,119.457,124.21799999999999,127.218,131.513,136.274,141.223,145.985,147.572,152.701,155.677,160.806,165.37900000000002,168.376,173.505,178.078,180.875,183.117,188.066,190.864,198.234,202.807,207.93599999999998,210.951,215.9,220.661,223.65,226.259,231.02,235.59300000000002,238.616,242.911,247.484,249.726,254.298,256.908,261.014,264.014,268.964,271.206,274.219,278.792,283.553,286.162,287.749,291.013,296.24,301.467,308.094,312.855,315.83,320.402,325.531,332.901,334.489,339.25,340.837,345.132,347.741,350.538,355.111,357.72,359.307,364.257,369.01800000000003,372.067,373.654,378.415,381.422,386.55,391.123,393.732,395.32,399.892,404.653,407.263,411.558,414.53,421.156,422.743,425.352,430.113,433.125,438.254,439.841,442.082,444.324,448.897,451.694,456.267,461.028,463.637,466.629,471.202,476.152,478.949,483.71,488.283,492.856,494.443,497.469,502.598,504.185,508.48,513.429,516.227,521.355,525.928,528.726,533.02" y="332.793" svg_rhmargin="535.441" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">research should be performed on the safety of anti-VEGF administration in patients with different corneal disorders.</text>
  <text svg_rhmargin="159.934" x="91.276,97.915,104.052,110.189,114.254,120.131,125.439,127.758,133.648,137.131,139.451,145.588,151.478,157.033,159.934" y="347.987" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Abbreviations: </text>
  <text svg_rhmargin="202.195" x="163.559,168.132,172.893,175.502,177.089,180.353,185.58,190.808,197.434,202.195" y="347.987" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-VEGF </text>
  <text svg_rhmargin="210.278" x="204.208,210.278" y="347.987" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text svg_rhmargin="364.856" x="212.259,216.831,221.592,224.202,225.789,229.895,234.468,238.763,243.336,248.097,249.684,254.257,257.05400000000003,259.085,263.658,268.419,273.548,278.497,281.106,285.867,290.44,292.027,293.614,298.187,299.774,301.774,306.723,309.521,314.47,321.096,323.705,328.466,330.516,332.758,337.33,341.903,344.512,349.462,352.259,354.68,356.651,362.901,364.856" y="347.987" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">antivascular endothelial growth factor, CI </text>
  <text svg_rhmargin="372.987" x="366.917,372.98699999999997" y="347.987" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text x="374.968,379.541,384.49" y="347.987" svg_rhmargin="389.251" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">con</text>
  <text x="389.255" y="347.987" svg_rhmargin="393.173" style="fill:#171615;font-family:DPNDFO+AdvOT6e5d2ec0+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text svg_rhmargin="471.836" x="393.167,398.296,402.869,407.63,412.203,416.77599999999995,418.792,420.379,425.14,427.749,432.322,435.12,439.226,443.799,445.386,449.681,452.102,454.11,460.36,466.609,471.83599999999996" y="347.987" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">dence intervals, CNV </text>
  <text svg_rhmargin="479.911" x="473.841,479.911" y="347.987" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text x="481.892,486.465,491.414,494.212,498.973,503.546,508.119,509.706,511.711,516.473,521.045,525.995,530.101,534.674,538.969,543.542,548.303,549.89,554.463,557.26,558.847,562.954,567.527,570.136,571.723,576.672,581.433" y="347.987" svg_rhmargin="583.854" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">corneal neovascularization,</text>
  <text svg_rhmargin="103.874" x="91.276,97.902,103.873" y="357.965" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">OR </text>
  <text svg_rhmargin="112.937" x="106.867,112.93700000000001" y="357.965" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text svg_rhmargin="181.806" x="115.938,120.887,126.016,131.145,135.44,138.444,141.242,145.815,148.424,150.011,154.96,159.255,161.676,164.636,170.607,176.857,181.806" y="357.965" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">odds ratios, RCT </text>
  <text svg_rhmargin="190.89" x="184.82,190.89" y="357.965" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text svg_rhmargin="322.822" x="193.891,196.689,201.261,206.023,211.151,216.101,223.471,225.058,229.165,233.737,238.86599999999999,241.908,246.481,251.431,256.192,258.801,261.598,266.548,268.135,269.722,274.295,279.42400000000004,282.442,285.051,287.849,289.436,294.009,295.596,298.017,300.98,306.207,311.435,318.061,322.822" y="357.965" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">randomized controlled trial, VEGF </text>
  <text svg_rhmargin="331.886" x="325.816,331.88599999999997" y="357.965" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:8.97px;font-style:NORMAL;font-weight:normal;">= </text>
  <text x="334.887,338.994,343.566,347.861,352.434,357.195,358.782,363.355,366.15200000000004,369.185,373.758,378.519,383.648,388.597,391.206,395.967,400.54,402.127,403.714,408.287,409.87399999999997,412.894,417.843,420.641,425.59,432.216,434.825,439.586,442.544,444.785,449.358,453.931,456.54,461.489,464.287" y="357.965" svg_rhmargin="466.708" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">vascular endothelial growth factor.</text>
  <text svg_rhmargin="142.36" x="91.276,98.162,104.14,109.28,117.665,123.702,127.767,133.904,139.459,142.36" y="372.932" style="fill:#171615;font-family:DPNDFN+AdvOT91f5f621.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Keywords: </text>
  <text x="145.02,149.593,154.722,158.829,163.401,166.199,170.494,175.067,178.071,182.644,186.75,191.323,196.084,198.694,201.11499999999998,204.092,208.665,213.426,216.035,217.622,221.729,226.302,230.597,235.169,239.931,241.518,246.09,248.887,251.939,256.512,261.273,266.402,271.351,273.96,278.721,283.294,284.881,286.468,291.041,292.628,295.591,300.54,303.338,308.287,314.913,317.522,322.283,325.297,327.538,332.111,336.684,339.293,344.243,347.04,349.461,352.509,357.082,361.843,364.452,366.039,369.303,374.53,379.757,386.383,391.145,393.566,396.557,401.507,406.08,410.841,412.428,417.001,419.798,422.805,427.378,432.139,434.749,439.321,442.119,443.706,448.655,451.452,454.439,458.733,463.306,468.256,475.626,480.199,484.96,487.569,489.99,493.045,497.34,501.912,504.154,508.727,511.336" y="372.932" svg_rhmargin="515.443" style="fill:#171615;font-family:DPNDFL+AdvOT6e5d2ec0;font-size:8.97px;font-style:NORMAL;font-weight:normal;">adverse event, antivascular endothelial growth factor, anti-VEGF, ocular anterior segment, safety</text>
  <text x="85.039,90.955,93.908,98.646,101.599,107.514,111.158,115.095,120.812,126.727,132.643,138.16,141.804,144.558,150.275" y="436.428" svg_rhmargin="156.19" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">1. Introduction</text>
  <text x="85.039,91.477,95.96,99.412,103.331,108.28,110.701,115.184,118.636,120.982,124.9,129.849,134.799,139.748,142.635,147.585,151.503,153.924,156.345,160.828,163.249,165.597,170.08,173.532,178.482,185.386,188.273,193.222,195.53,198.417,202.901,206.819,209.706,214.655,218.107,220.474,223.362,229.799,235.215,242.119,247.069,249.956,252.278,254.699,258.151,260.498,264.981,267.244,274.149,278.067,280.488,282.909,285.796,289.714,293.166,296.053,300.536,305.486,307.907,310.328,313.78,318.729,322.647,327.597" y="452.359" svg_rhmargin="330.018" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Vascular endothelial growth factor (VEGF) is a well-established,</text>
  <text x="85.039,89.989,94.938,97.825,101.744,106.693,109.58,112.988,117.938,121.39,126.339,129.226,133.709,138.659,143.142,145.563,150.512,154.995,158.914,163.863,166.284,170.202,173.647,178.13,181.582,186.532,193.436,196.323,201.27200000000002,204.657,207.544,212.027,215.946,218.833,223.782,227.234,229.655,233.06,238.475,240.896,245.846,249.764,254.713,259.196,264.146,268.064,271.496,276.446,279.333,282.721,289.159,294.575,301.479,306.428,309.82,314.77,318.222,320.642,325.592" y="463.358" svg_rhmargin="330.075" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">potent pro-angiogenic growth factor. Blockade of VEGF using</text>
  <text svg_rhmargin="330.137" x="85.039,89.523,94.472,97.359,99.78,102.667,109.105,114.521,121.425,126.374,129.032,133.515,137.998,141.916,146.866,149.753,153.20499999999998,155.846,160.796,165.279,168.731,171.38,176.329,180.247,184.165,189.114,191.732,198.636,201.057,206.006,209.925,212.346,216.829,219.511,224.46,227.912,231.83,236.77900000000002,239.41,241.83,246.77900000000002,249.387,253.306,255.726,258.147,263.097,265.518,269.436,273.919,276.34,278.98,282.432,286.35,289.237,292.124,294.545,299.495,303.978,307.43,310.103,314.587,318.039,320.705,325.188,330.137" y="435.692" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anti-VEGF agents has been widely used in clinical settings as an </text>
  <text x="345.091,349.574,354.523,356.944,361.894,366.843,370.761,373.648,378.822,381.709,386.659,390.111,395.263,398.15,401.602,405.52,410.003,412.89,415.311,420.261,424.744,429.958,434.441,438.924,442.842,445.729,449.181,453.1,455.521,460.004,462.891,466.809,471.75800000000004,476.955,484.325,488.808,492.726,497.676,500.097,504.58,508.032,513.237,518.186,522.104,526.588,530.506,535.455,539.374,542.826,547.309,550.196,552.617,557.566" y="435.692" svg_rhmargin="562.515" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">adjunct for treating age-related macular degeneration</text>
  <text svg_rhmargin="570.551" x="562.507,564.673,568.386,570.5509999999999" y="435.691" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[1] </text>
  <text x="575.773,580.256,585.206" y="435.691" svg_rhmargin="590.155" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">and</text>
  <text x="345.089,350.038,352.459,356.942,361.892,365.81,368.697,371.118,375.036,380.011,387.381,391.864,395.783,400.732,403.153,407.636,411.088,416.066,419.985,424.934,428.852,436.223,440.706,443.127,448.097,452.58,456.032,460.966,467.87,471.788,474.209,476.63,481.602,486.085,489.537,494.528,499.011,503.96,506.847,510.766,514.218,516.639,521.588,525.04,530.016,533.468,537.387,541.87,549.24,553.158,558.108,560.9949999999999,565.959,570.908,574.826,579.776,582.197,586.68" y="446.633" svg_rhmargin="590.132" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">diabetic macular edema, as well as anterior segment ocular</text>
  <text x="345.089,350.038,352.459,355.911,359.83,364.313,367.765,371.683,375.135,380.407,384.89,388.342,391.794,396.744,400.662,403.083,407.566,410.453,414.372,419.321,424.626,431.53,433.951,436.838,441.78700000000003,447.076,452.026,455.944,460.893,465.376,469.86,473.312,477.23,482.179,484.6,489.083,492.535,494.956,498.875,503.358,506.245,508.666,513.615,518.565,520.9860000000001,526.273,529.725,534.674,538.593,543.5419999999999,548.837,553.32,556.772,562.046,565.964,570.913,574.365,579.315,583.233,587.716" y="457.631" svg_rhmargin="590.137" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">diseases associated with neovascularization, such as corneal</text>
  <text x="345.089,350.038,353.957,358.906,363.389,367.872,371.324,375.243,380.192,382.613,387.096,390.548,392.969,396.887,401.37,404.258,406.679,411.628,416.577,419.751,422.638,429.075,436.446,442.884,445.771,448.192,451.384,456.333,459.22,463.138,466.59,471.074,475.557,477.978,482.927,490.297,492.718,495.886,500.369,505.319,510.26800000000003,513.404,518.353,522.271,527.221,531.704,536.187,539.639,543.557,548.507,550.928,555.411,558.8629999999999,562.044,566.527,568.948,573.431,578.381,582.299,587.248" y="468.573" svg_rhmargin="590.135" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">neovascularization (CNV), pterygium, and neovascular glauco-</text>
  <text x="345.089,352.459,356.942" y="479.514" svg_rhmargin="359.363" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ma.</text>
  <text x="359.376,361.542" y="475.547" svg_rhmargin="365.254" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[2</text>
  <text x="365.272" y="475.547" svg_rhmargin="368.634" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:5.98px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="374.495" x="368.617,372.33,374.495" y="479.515" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">4] </text>
  <text x="378.765,385.203,387.624,390.511,395.461,400.41,405.359,409.842,414.791,419.016,421.437,424.324,428.54,433.489,437.972,441.424,445.661,450.61,454.529,458.447,463.396,467.657,471.109,475.027,479.977,484.926,488.378,491.265,495.184,500.13300000000004,504.337,507.224,512.173,516.656,519.5429999999999,523.838,528.321,533.271,536.158,538.579,541.466,547.904,553.319,560.224,565.173,569.418,573.901,578.384,582.302,587.252" y="479.515" svg_rhmargin="590.139" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Although it has been reported that anti-VEGF agent</text>
  <text x="345.09,347.977,351.429,355.347,359.83,362.717,370.088,374.006,378.955,381.842,384.49,386.911,390.363,393.051,396.503,400.986,403.874,407.79200000000003,410.456,414.939,419.888,424.837,427.463,431.381" y="490.513" svg_rhmargin="434.268" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">treatment is safe and ef</text>
  <text x="434.268" y="490.513" svg_rhmargin="439.217" style="fill:#171615;font-family:DPNDHD+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="439.256,443.175,445.596,449.514,454.463,457.35,460.005,462.426,467.375,470.04,474.989,479.472,482.359,484.78,488.698,493.648,496.535,499.987,502.637,509.541,511.961,514.849,519.798,522.479,525.931,529.849,532.736,535.157,540.107,544.59,547.0110000000001,549.691,554.64,557.061,560.513,564.431,568.915,572.367,576.285,579.737,582.158,584.839,587.26" y="490.513" svg_rhmargin="590.147" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cient in patients with retinal diseases, it</text>
  <text x="345.089,350.038,354.521,357.973,361.303,365.786,368.207,371.659,376.608,380.011,384.96,388.878,392.797,397.74600000000004,401.157,404.609,408.527,413.477,418.426,421.878,424.765,428.683,433.632,437.043,439.93,444.879,449.362,452.249,455.638,458.059,463.008,465.895,469.347,473.831,478.314,480.735,483.622,487.074,490.992,495.475,497.896,501.274,503.695,508.644,511.065,514.983,518.901,521.789,524.209,529.159,534.108,537.556,542.505,545.3919999999999,548.781,553.264,558.213,561.1,563.521,566.409,572.846,578.262,585.166" y="501.455" svg_rhmargin="590.115" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">has also been reported that intravitreal injection of anti-VEGF</text>
  <text x="345.089,349.572,354.055,357.973,362.923,365.81,369.262,371.79,375.709,380.658,385.608,388.028,392.97700000000003,395.544,397.965,402.914,407.864,412.813,416.731,420.649,423.21,426.662,431.145,434.597,437.484,441.402,448.772,451.193,455.111,457.678,462.161,467.11,471.593,475.512,478.964,482.416,486.334,488.915,493.398,498.347,503.296,505.865,510.815,514.733,519.682,522.103,526.586,530.038,532.567,537.05,542.0,546.483,550.401,553.853,557.305,561.223,563.804,567.722,570.609,573.496,577.415,581.333,584.22,587.672" y="512.396" svg_rhmargin="590.093" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">agents could induce systemic adverse and ocular adverse effects,</text>
  <text x="345.089,348.541,353.49,357.408,362.357,365.498,369.981,373.433,376.61,380.528,385.477,390.427,395.376,400.326,405.275,408.162,413.112,417.595,420.016,427.386,429.807,432.694,435.115,438.567,440.988,444.185,453.152,455.572,458.46,463.409,466.579,470.031,473.949,478.432,482.915,486.367,491.317,494.769,497.929,500.816,505.765,508.927,511.348,514.235,517.687,520.889,524.341,528.824,531.712,535.63,538.517,543.0,546.173,549.06,554.01,557.462,560.63,563.517,566.969,570.887,575.37,578.257,580.678,585.628" y="523.394" svg_rhmargin="590.111" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">such as endophthalmitis. With regards to its safety for treating</text>
  <text x="345.089,349.572,354.521,357.408,361.327,364.779,367.2,372.149,375.601,378.593,382.045,385.963,390.447,397.817,401.735,406.685,409.572,412.551,417.501,419.922,423.374,428.323,431.775,436.724,440.643,444.095,447.547,449.968,453.029,455.916,460.865,464.783,467.768,471.687,476.636,481.586,485.504,487.925,492.874,496.326,498.747,503.696,508.646,512.0980000000001,515.105,519.588,523.04,526.958,529.959,533.877,538.826,543.776,546.663,550.115,555.064,559.548,563.466,566.918,570.37,572.791,577.274,579.695" y="534.336" svg_rhmargin="582.116" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">anterior segment disorders, the conclusions are controversial.</text>
  <text x="354.046,359.928,364.877,366.802,370.72,375.203,379.686,382.107,387.056,391.54,394.427,398.345,400.306,407.21,412.159,416.078,418.965,423.914,427.833,431.285,433.244,436.131,441.08,444.998,446.907,451.39,456.339,463.709,466.13,471.08,473.501,476.953,479.84,483.292,487.775,490.662,493.083,498.032,502.981,504.958,509.907,512.794,514.765,519.248,524.197,526.104,530.587,535.537,538.424,540.845,543.732,550.17,555.585,562.489,567.438,569.416,573.899,578.382,582.3,587.25" y="545.278" svg_rhmargin="590.137" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">To evaluate whether the administration of an anti-VEGF agent</text>
  <text x="345.089,347.976,352.925,356.377,358.525,361.412,364.864,368.782,373.265,376.153,378.573,383.523,388.00600000000003,390.215,394.698,399.648,402.535,406.453,409.905,412.326,417.276,420.728,422.983,426.435,430.353,434.836,442.206,446.125,451.074,453.961,456.147,461.097,463.517,466.97,470.888,475.371,478.823,482.741,486.193,488.404,495.308,497.729,500.15,502.57099999999997,504.788,507.209,511.128,515.611,520.56,522.76,525.647,530.596,532.794,537.2769999999999,539.427,542.879,545.3,548.752,553.7009999999999,555.924,560.874,563.761,565.958,570.908,574.826,579.775,582.196,586.68" y="556.219" svg_rhmargin="590.132" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">for treating anterior segment diseases will lead to a risk of ocular</text>
  <text x="345.089,349.572,354.521,359.004,362.923,366.375,369.827,373.745,380.918,384.836,389.32,393.238,398.187,401.074,404.526,411.759,415.677,420.626,427.997,432.946,437.429,440.881,444.799,449.748,456.942,463.846,466.267,469.154,474.103,481.319,486.269,488.689,493.173,497.091,501.009,505.959,510.908,513.3290000000001,520.549,527.454,531.372,538.577,543.527,547.445,550.897,553.784,558.733,562.185,569.556,573.474,578.423,585.63" y="567.217" svg_rhmargin="590.113" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">adverse events compared with placebo, we performed a</text>
  <text x="345.089,348.541,353.024,356.476,359.363,363.281,370.652,375.135,378.022,380.443,384.361,387.437,390.889,394.807,399.29,401.711,405.629,412.533,415.612,420.095,425.045,429.994,433.073,440.444,444.362,447.249,451.732,454.619,459.103,464.052,468.535,470.956,475.439,478.891,481.312,484.764,487.837,492.786,495.673,498.778,503.262,505.682,508.103,511.138,514.59,518.508,520.929,524.847,529.33,533.813,538.763,541.65,544.755,548.207,552.69,557.64,562.589,567.538,574.909,577.33,581.248,585.166" y="578.159" svg_rhmargin="590.115" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">systematic review and meta-analysis of all relevant randomized</text>
  <text x="345.089,349.007,353.956,358.906,361.793,365.245,370.194,372.615,375.036,378.954,383.903,386.87,389.757,393.209,395.63,400.113,402.534,405.986,409.036,411.924,418.361,424.799,430.681,434.133,437.02" y="589.1" svg_rhmargin="439.441" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">controlled trials (RCTs).</text>
  <text x="345.09,351.005,353.95799999999997,358.639,367.309,373.025,376.669,382.585,388.301,394.217" y="618.7529999999999" svg_rhmargin="399.441" style="fill:#171615;font-family:DPNDFJ+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">2. Methods</text>
  <text x="345.09,350.039,352.46,357.409,359.83,364.308,370.091,375.041,379.99,383.254,388.203,393.332,396.338,400.822,403.709,406.972,411.922,414.809,419.758,424.986" y="636.7239999999999" svg_rhmargin="429.469" style="fill:#171615;font-family:DPNDHE+AdvOT01861455.I;font-size:8.97px;font-style:NORMAL;font-weight:normal;">2.1. Search strategy</text>
  <text x="345.09,351.52799999999996,354.274,357.726,362.209,365.661,368.548,372.466,379.837,384.32,387.207,389.628,393.546,396.395,399.847,403.765,408.248,411.7,415.619,420.56800000000004,423.38,428.329,431.216,433.982,436.869,441.818,445.736,448.551,450.972,453.393,456.28,460.198,463.65,468.133,471.02,475.97,479.422,483.34000000000003,486.137,489.024,492.476,496.394,500.312,503.144,506.596,509.483,512.935,517.418,520.306,524.224,528.707,533.19,535.6110000000001,538.406,542.889,547.838,552.788,557.737,560.158,564.076,571.447,575.365,580.314,583.201,587.685" y="652.655" svg_rhmargin="590.106" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">A systematic search of the literature (see strategy, Supplemental</text>
  <text x="345.09,351.994,354.415,358.898,361.319,364.206,368.689,371.11,379.728,386.166,391.116,396.065,398.952,402.87,407.82,410.707,419.356,424.305,426.726,435.343,440.292,443.179,446.066,451.016,453.437,455.858,458.278,460.699,463.12,468.07,473.019,476.471,478.892,481.313,488.217,495.121,497.542,501.46,506.41,513.78,516.201,525.167,532.071,534.492,540.93,545.879,550.829,555.778,558.1990000000001,566.979,573.883,578.832,581.253,585.171" y="663.596" svg_rhmargin="590.12" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Digital Content 1, http://links.lww.com/MD/C411, which</text>
  <text x="345.09,350.039,353.957,357.409,361.328,364.78,367.201,372.15,375.037,378.489,383.186,386.073,391.022,394.94,399.683,402.57,407.519,409.94,412.361,417.031,420.483,424.401,428.884,432.336,436.255,441.204,445.944,449.396,452.283,455.735,460.218,463.105,467.023,471.506,475.989,480.695,483.582,488.532,491.984,496.682,499.569,504.519,508.437,513.179,518.129,520.549,523.437,526.324,530.242,533.694,537.612,542.562,545.449,550.142,555.091,559.574,562.461,566.945,571.894,576.377,579.829,583.747,587.2" y="674.538" svg_rhmargin="590.087" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">descripts the full search strategy for the different databases)</text>
  <text x="345.09,351.994,356.477,359.929,362.494,367.444,371.362,374.814,377.701,382.65,386.102,393.473,397.391,402.34000000000003,405.012,411.916,414.337,417.224,422.174,427.123,432.073,434.96,437.609,441.061,444.98,448.432,451.319,454.771,457.192,461.11,463.997,466.418,471.367,476.31600000000003,478.937,481.824,486.773,489.368,492.82,496.739,501.222,503.643,508.592,513.541,516.993,519.4140000000001,522.079,527.029,531.978,536.927,539.348,541.769,545.687,550.171,553.058,555.479,560.428,565.377,567.999,570.886,575.369,580.319,584.237,587.689" y="685.5360000000001" svg_rhmargin="590.11" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">was performed without restriction to regions, publication types,</text>
  <text x="345.09,350.039,353.491,355.465,357.885,362.369,367.318,371.801,376.751,381.234,385.717,389.635,393.087,395.091,397.512,402.461,404.446,409.395,413.878,416.765,421.249,426.198,430.681,434.133,438.051,441.503,443.506,446.958,451.907,455.825,460.774,462.781,467.264,470.716,472.702,480.072,484.555,486.976,491.925,493.961,502.927,508.343,515.247,520.662,523.55,530.92,536.3349999999999,538.349,541.237,546.186,551.135,556.085,561.034,563.01,565.898,570.847,572.875,576.327,581.277,586.226" y="696.478" svg_rhmargin="590.144" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">or languages in databases such as Ovid MEDLINE (1986 to June</text>
  <text x="345.09,350.039,352.46,355.917,360.867,365.816,370.766,375.715,378.602,381.02299999999997,384.547,389.962,398.929,404.344,410.782,415.265,420.68,424.174,427.061,432.011,436.96,441.91" y="707.419" svg_rhmargin="446.859" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">1, 2016), EMBASE (1986</text>
  <text x="446.854" y="707.419" svg_rhmargin="451.337" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="451.332,456.282,461.231,466.18,471.13,473.551,477.07,480.522,485.471,490.421,494.339,497.819,502.768,505.656,508.077,511.595,516.544,521.494,526.443,535.409,539.328,544.2769999999999,547.764,556.73,562.146,569.05,574.466,577.353,584.723" y="707.419" svg_rhmargin="590.139" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">2016, June 1), PubMed MEDLINE</text>
  <text x="345.09,347.977,352.926,357.876,362.825,367.774,370.771,373.658,378.607,381.6,385.052,390.001,394.95,398.868,401.838,406.788,409.209,412.213,417.163,422.112,427.061,432.011,434.898,437.319,440.332,444.815,449.764,454.713,457.68,464.117,469.533,476.903,482.785,489.223,495.661,501.076,504.11,506.997,511.946,516.896,521.845" y="718.417" svg_rhmargin="526.794" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(1986 to June 1, 2016), and CENTRAL (1986</text>
  <text x="526.791" y="718.417" svg_rhmargin="531.274" style="fill:#171615;font-family:DPNDHC+AdvOTbc475f09+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="531.27,536.219,541.168,546.118,551.067,553.488,556.497,559.949,564.899,569.848,573.766,576.736,581.685,584.572" y="718.417" svg_rhmargin="586.993" style="fill:#171615;font-family:DPNDHB+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">2016, June 1).</text>
  <path d="M85.039 169.405 L566.248 169.405 C579.416 169.363 590.182 180.153 590.115 193.329 L590.115 381.663 L85.039 381.663 M85.039 169.405 L566.248 169.405 L566.248 169.632 L85.265 169.632 M566.249 169.405 L569.991 169.688 C580.168 171.28 588.287 179.398 589.833 189.588 L590.117 193.329 L589.89 193.329 L589.606 189.588 C587.996 179.388 580.067 171.634 569.934 169.915 L566.249 169.632 M590.116 193.328 L590.116 381.662 L589.889 381.378 L589.889 193.328 M590.116 381.662 L85.039 381.662 L85.266 381.38 L589.889 381.38 M85.039 381.662 L85.039 169.405 L85.265 169.631 L85.265 381.38 M85.039 489.776 L330.122 489.776 L330.122 719.212 L85.039 719.212 " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 85.03900146484375 310.5069885253906 L 330.06597900390625 310.5069885253906 L 330.06597900390625 309.9969787597656 L 85.03900146484375 309.9969787597656 L 84.81200408935547 310.1099853515625 L 84.81200408935547 310.39398193359375" style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="85.039,89.029,93.019,94.254,96.284,100.134,102.311,104.194,106.585,112.465,116.168,119.872,123.429,129.163,134.896,138.453,142.442,144.854,149.214,152.917,156.475,160.179,163.08,166.638,170.627,172.976,177.336,180.677,181.912,185.469,191.202" y="498.054" svg_rhmargin="193.085" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Editor: Muhammad Shahzad Aslam.</text>
  <text x="85.039,89.398,91.936,93.966,98.827,101.196,104.753,108.456,112.44500000000001,114.802,119.447,121.985,125.326,129.176,131.525,135.082,138.932,142.635,144.664,146.84,148.074,152.063,155.766,157.796,161.352,165.341,167.749,171.306,175.295,178.998,182.555,183.789,185.023,188.21699999999998,190.595,192.624,196.474,198.815,200.844,204.547,205.782,209.12300000000002,211.457,216.611,220.46,222.636,225.83" y="509.959" svg_rhmargin="227.713" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">S-tH and B-sT contributed equally to this work.</text>
  <text x="85.039,88.89,92.593,96.15,98.477,104.21,107.767,111.471,115.258,118.599,122.157,124.333,125.568,129.558,131.587,133.913,137.616,141.174,144.51500000000001,146.896,150.599,154.45,156.47899999999998,158.802,162.792,166.349,169.906,173.609,175.981,179.971,182.148,185.705,189.046,192.603,196.307,198.337,201.895,205.88400000000001,208.299,211.857,213.886,216.18,219.737,223.441,226.635,228.993,234.727,238.284,241.841,243.871,245.106,248.895,252.745,256.086" y="521.921" svg_rhmargin="257.969" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">The manuscript has not been presented at any meetings.</text>
  <text x="85.039,89.761,93.319,96.66,97.895,101.745,105.44800000000001,107.832,111.682,113.426,115.712,119.053,121.083,124.787,128.777,131.97099999999998,134.366,136.11,140.469,143.008,146.203,150.193,151.937,153.82000000000002,156.195,159.753,163.603,167.307,171.296,175.0,178.557,180.58599999999998,182.956,186.807,188.551,190.894,194.235,196.265,199.969,203.959,207.153,209.491,211.235,215.595,218.134,220.164,225.025,226.841,228.72400000000002,231.037,234.594,238.444,239.679,240.914,244.472,248.029,250.059,251.294,255.144,258.933,260.816,263.129,268.862,272.419,276.123,279.68,283.531,287.088,292.821,296.466,300.17,302.2" y="533.884" svg_rhmargin="304.083" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Design of study (S-yZ); conduct of study (S-tH); collection, management,</text>
  <text x="85.039,88.596,92.299,95.856,97.09,100.284,103.625,104.859,108.199,110.082,112.476,116.033,119.736,123.72500000000001,126.082,127.317,131.02,133.049,136.606,138.782,142.771,144.946,148.503,150.532,154.089,156.118,157.353,161.202,164.905,167.295,171.145,172.889,175.232,179.222,182.779,184.808,188.36499999999998,190.709,192.453,196.811,199.35,201.379,206.24,208.12300000000002,210.493,215.138,217.677,221.017,224.867,226.75,229.145,234.298,238.287,240.031,241.91400000000002,244.281,248.27,250.446,254.003,257.992,261.548,263.724,267.281,269.31,270.545,274.394,278.097,280.505,284.356,286.1,288.443,290.472,294.175" y="542.841" svg_rhmargin="297.732" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">analysis, and interpretation of data (S-tH, B-sT, OX); preparation of the</text>
  <text x="85.039,90.773,94.33,98.034,101.737,105.079,108.636,110.893,112.128,116.118,118.14699999999999,120.475,122.219,126.578,129.117,131.147,136.009,137.892,140.262,145.416,149.406,151.28900000000002,153.642,157.632,160.171,161.406,165.396,167.14,169.023,171.389,174.946,178.65,182.639,184.996,187.173,190.73,193.925,195.16,198.717,203.871,206.258,209.815,213.519,217.508,219.865,223.423,227.412,231.402,233.579,237.429,240.624,244.181,245.41500000000002,247.761,251.611,253.355,255.698,257.728,261.432,264.98900000000003,267.321,273.054,276.611,280.315,284.102,287.444,291.001,293.177,294.412,298.402,300.431,302.757,304.5,308.859,311.399,314.593,318.583,320.327" y="551.855" svg_rhmargin="322.21" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">manuscript (S-tH, OX, Y-jY); and review and approval of the manuscript (S-yZ).</text>
  <text x="85.039,88.89,92.593,96.15,98.477,102.034,105.738,107.768,111.472,115.322,117.584,120.925,123.253,126.957,130.514,133.709,137.266,139.582,143.285,147.135,149.503,153.06,156.91" y="563.761" svg_rhmargin="160.613" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">The authors have no con</text>
  <text x="160.611" y="563.761" svg_rhmargin="163.659" style="fill:#171615;font-family:DPNDHF+AdvOT1deab444.I+fb;font-size:6.97px;font-style:NORMAL;font-weight:normal;">ﬂ</text>
  <text x="163.672,164.907,168.463,170.493,173.834,176.201,180.05,181.794,184.081,185.315,189.018,191.047,194.681,196.857,200.414,203.754,205.783,208.117,210.146,213.99599999999998,216.337,220.326,221.56,224.9,228.457,229.691,233.541,236.881,240.438" y="563.761" svg_rhmargin="242.321" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">icts of interest to disclose.</text>
  <text x="85.039,89.398,93.101,97.09,101.079,102.313,105.87,111.683,115.239,118.943,120.972,124.529,125.76299999999999,128.123,132.844,134.078,137.928,139.162,141.192,144.748,145.982,148.304,153.164,157.014,160.717,162.816,166.373,170.076,172.105,174.437,175.672,179.013,181.354,184.91,188.104,191.661,192.895,194.13,197.686,201.675,202.91,206.46699999999998,208.848,210.591,214.441,216.617,218.939,220.969,224.672,225.906,229.247,231.581,235.138,237.314,239.343,240.651,244.208,245.442,248.999" y="575.723" svg_rhmargin="250.882" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Supplemental Digital Content is available for this article.</text>
  <text x="85.039,89.399,91.429,94.986,97.016,100.57300000000001,102.956,107.455,111.012,114.206,116.562,120.266,123.823,127.813,131.663,133.84,137.397,139.427,143.278,145.454,148.648,151.035,154.886,156.63,158.973,164.127,168.117,171.821,173.851,177.555,181.112,182.347,188.08,191.93,193.165,197.016,200.866,204.162,206.04500000000002,208.357,212.347,216.051,219.901,223.605,227.455,230.796,234.5,238.057,241.76,244.133,249.287,253.277,256.981,259.011,262.714,266.358,267.593,273.326,274.561,278.118,280.476,285.337,288.895,292.599,294.629,298.186,300.36199999999997,302.702,306.259,308.288,310.639,314.998,318.702" y="587.685" svg_rhmargin="322.405" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center at Sun</text>
  <text x="85.039,89.029,92.586,94.617,97.156,100.497,104.054,107.757,110.157,115.018,118.722,119.957,123.152,126.709,128.886,132.227,133.462,135.492,138.687,140.57000000000002,142.93,148.145,151.849,155.406,159.11,162.96,165.862,169.566,173.416,177.12,179.00300000000001,181.37,186.231,189.935,191.17,194.874,198.431" y="596.642" svg_rhmargin="200.314" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Yat-sen University, Guangzhou, China.</text>
  <text svg_rhmargin="87.759" x="85.039,87.759" y="608.605" style="fill:#171615;font-family:DPNDFM+AdvOTb0c9bf5d+22;font-size:4.65px;font-style:NORMAL;font-weight:normal;">∗ </text>
  <text x="88.951,93.813,97.663,99.839,102.016,105.573,108.914,112.904,116.754,120.458,124.448,128.005,131.709,135.266,138.824,140.70700000000002,143.154,147.514,151.217,152.453,154.992,158.186,162.037,165.74,168.102,172.091,175.795,179.645,183.349,185.232,187.605,191.456,195.159,198.71599999999998,201.042,205.402,207.432,210.989,213.019,216.576,218.959,223.458,227.015,230.20899999999997,232.509,236.213,239.77,243.76,247.61,249.858,253.416,255.446,259.296,261.473,264.66700000000003,267.038,270.888,272.632,274.918,280.134,284.124,287.827,289.857,293.561,297.118,298.354,304.087,307.937,309.172,313.022,316.872,320.067" y="608.605" svg_rhmargin="321.95" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Correspondence: Shi-you Zhou, The State Key Laboratory of Ophthalmology,</text>
  <text x="85.04,89.029,92.733,96.583,100.287,104.203,107.544,111.248,114.805,118.50800000000001,120.815,125.97,129.959,133.663,135.693,139.397,143.041,144.276,150.009,151.244,154.801,157.158,162.02,165.577,169.281,171.311,174.868,177.04399999999998,179.384,182.941,184.97,187.322,191.681,195.385,199.088,201.439,205.428,208.986,211.016,213.555,216.896,220.453,224.156,226.556,231.418,235.121,236.356,239.551,243.109,245.285,248.626,249.861,251.891,255.086,256.969,259.329,264.545,268.248,271.806,275.509,279.36,282.262,285.965,289.816,293.51899999999995,295.898,299.748,303.599,307.449,311.299,315.149,318.999" y="617.563" svg_rhmargin="320.882" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou 510060,</text>
  <text x="85.04,89.9,93.603,94.838,98.541,102.098,104.484,106.227,109.784,112.322,118.055,121.612,122.846,124.08,125.963,128.293,131.194,134.897,138.747,142.522,145.862,149.565,150.8,153.994,159.51,165.243,168.799,170.034,171.268,173.151,176.491,179.685,183.11,186.813,188.696,192.253,196.242,199.945,201.828,205.384,209.087,210.831" y="626.577" svg_rhmargin="212.714" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">China (e-mail: zhoushiy@mail.sysu.edu.cn).</text>
  <text svg_rhmargin="113.93" x="85.04,89.901,93.751,97.741,100.936,103.112,104.347,108.197,111.901,113.92999999999999" y="638.483" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Copyright </text>
  <text svg_rhmargin="121.564" x="116.334,121.565" y="638.483" style="fill:#171615;font-family:DPNDGB+AdvOTb0c9bf5d;font-size:6.97px;font-style:NORMAL;font-weight:normal;">© </text>
  <text x="123.874,127.724,131.574,135.425,139.275,141.619,143.65,147.353,150.91,153.242,157.601,161.305,163.335,167.039,170.889,173.143,174.887,178.228,179.973,181.85600000000002,184.199,188.559,192.262,196.252,197.487,198.722,202.063,205.767,209.325,213.314,215.667,219.657,222.851,225.192,231.511,235.361,236.596,238.626,242.258,244.435,247.776,250.082,254.581,255.816,259.52,264.674,268.232,270.408,272.818,277.679,281.236,284.794,286.029,288.059,291.763,293.64599999999996,296.008,297.528,301.232,304.789" y="638.483" svg_rhmargin="306.672" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">2018 the Author(s). Published by Wolters Kluwer Health, Inc.</text>
  <text x="85.039,88.888,92.592,93.826,97.16699999999999,99.495,100.729,104.07,106.412,109.969,113.672,115.993,119.904,123.893,127.45,131.153,133.453,137.01,140.566,144.123,147.68,151.02,154.36100000000002,156.752,160.309,162.485,164.514,165.749,169.305,170.54,174.09699999999998,176.48,180.469,181.703,185.044,187.073,189.249,190.483,194.472,198.176,200.205,203.762,207.751,210.153,213.856,217.559,221.548,225.105,227.28099999999998,229.654,231.683,235.386,238.94299999999998,241.276,243.305,246.862,249.038,254.77,258.111,260.493,264.344,266.088,268.431,270.46,274.164,277.721,280.052,284.913,287.089,290.645,294.202,296.231,297.466,300.66" y="647.4970000000001" svg_rhmargin="304.217" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">This is an open access article distributed under the terms of the Creative</text>
  <text x="85.039,89.9,93.751,99.484,105.217,109.067,112.771,116.112,118.489,122.849,124.879,126.909,129.085,130.32,134.31,138.014,140.044,141.279,145.129,148.938,151.476,156.338,160.188,163.891,166.229,171.091,174.941,180.674,186.407,189.965,192.141,195.698,196.934,200.588,201.822,204.16,207.864,209.099,212.656,216.213,219.917,223.258,226.815,229.164,233.014,234.898,238.748,241.07,242.814,247.676,252.537,257.182,261.254,263.793,268.654,273.516,275.26,277.143,279.51,284.665,288.368,291.926,294.102,297.659,300.034,301.269,303.298,305.647,306.881" y="656.454" svg_rhmargin="310.221" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is</text>
  <text x="85.039,89.029,92.586,94.762,100.496,101.731,105.072,108.413,109.648,113.728,114.963,118.52,120.816,122.846,126.696,129.037,133.026,136.877,142.031,145.735,146.97,150.82,154.377,158.463,160.346,162.658,165.998,169.702,173.26,175.436,178.993,180.876,183.238,185.415,188.972,194.705,195.94,199.135,201.018,203.423,205.453,207.629,211.187,214.89,218.232,219.976,223.826,226.002,231.736,233.619,235.968,239.525,243.228,247.217,249.575,253.564,257.268,258.503,259.738,263.806,267.51,271.49899999999997,273.841,275.871,279.575,283.132,285.464,290.618,294.468,296.645,299.839,302.189,306.179,308.355,312.206,315.4,316.635,320.625,324.182" y="665.4110000000001" svg_rhmargin="328.171" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">permissible to download, share, remix, transform, and buildup the work provided</text>
  <text x="85.039,86.274,88.303,90.652,91.887,95.228,97.569,101.559,103.736,107.586,111.576,115.133,117.309,118.545,121.739,124.105,127.662,128.897,130.927,134.485,138.474,140.357,142.702,146.552,150.256,153.813,156.195,161.35,165.2,167.376,170.57,172.921,176.478,180.035,183.739,187.443,191.293,193.322,195.656,199.646,203.20299999999997,205.578,209.281,212.622,216.18,220.169,222.529,226.087,229.937,235.67,241.403,244.961,247.137,250.695,252.012,255.569,256.804,258.039,261.233,263.579,268.733,269.968,271.998,275.702,279.552,283.256,285.28499999999997,287.619,291.608,295.166,297.342,303.154,304.389,307.73,311.071,312.306,316.156" y="674.3679999999999" svg_rhmargin="319.859" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">it is properly cited. The work cannot be used commercially without permission</text>
  <text x="85.039,86.783,88.96,92.81,98.543,100.914,102.943,106.647,110.20400000000001,112.536,113.771,117.621,121.325,123.502,127.205,130.763,131.998" y="683.325" svg_rhmargin="133.881" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">from the journal.</text>
  <text x="85.039,90.919,94.476,98.466,99.701,103.258,104.493,108.197,111.754,114.125,115.869,119.719,123.569,127.419,131.27,133.014,135.386,139.236,143.087,144.97,148.821,152.671,154.415,157.972,161.823,165.673,169.523,173.373,177.223" y="695.288" svg_rhmargin="178.966" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Medicine (2018) 97:34(e11960)</text>
  <text x="85.039,89.538,93.095,96.652,100.21,101.445,104.713,108.271,112.26,114.143,116.45,120.3,124.14999999999999,126.485,132.365,135.922,138.098,141.736,145.439,147.745,151.595,155.446,159.296,163.146,165.491,167.73700000000002,170.083,174.442,178.0,181.557,185.114,189.104,191.134,194.692,198.772,200.655,202.967,206.818,210.668,213.003,216.49,220.194,221.429,224.623,226.95,230.8,234.651,238.501" y="707.25" svg_rhmargin="242.351" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">Received: 29 March 2018 / Accepted: 27 July 2018</text>
  <text x="85.039,88.743,90.773,92.803,96.793,98.676,100.922,103.169,107.158,110.353,112.237,116.338,120.188,121.423,123.307,127.157,129.334,133.184,135.43,139.28,143.131,145.014,148.865,152.796,156.647,160.497,162.743,168.623,173.345,175.228,179.078,182.929,186.779,190.629,194.479,198.33,202.18,206.03,209.88,213.731,217.658,221.57,225.42,229.27,233.121" y="719.212" svg_rhmargin="236.971" style="fill:#171615;font-family:DPNDGA+AdvOT1deab444.I;font-size:6.97px;font-style:NORMAL;font-weight:normal;">http://dx.doi.org/10.1097/MD.0000000000011960</text>
  <path d=" M 85.03900146484375 759.968017578125 L 590.1729736328125 759.968017578125 L 590.1729736328125 760.9884033203125 L 85.03900146484375 760.9884033203125 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 85.03900146484375 761.0460205078125 L 89.00749969482422 761.0460205078125 L 89.00749969482422 775.9559936523438 L 85.03900146484375 775.9559936523438 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text svg_rhmargin="304.422" x="91.389,98.751,104.769,111.195,115.239,122.393,133.171,140.115,144.16,146.651,153.39600000000002,156.756,164.845,171.998,178.299,180.789,187.943,197.697,201.032,207.976,214.721,221.874,225.24,235.919,243.073,247.117,254.153,258.925,266.805,273.55,280.572,283.062,289.08,295.506,297.996,304.42199999999997" y="31.899" style="fill:#73828a;font-family:DPNDHG+AdvOTbed05995;font-size:9.96px;font-style:NORMAL;font-weight:normal;">Systematic Review and Meta-Analysis </text>
  <text x="437.272,469.714,489.657,511.847,519.123,537.736,545.012,564.991" y="31.899" svg_rhmargin="587.342" style="fill:#de000f;font-family:DPNDJH+Avenir-Roman;font-size:40.2px;font-style:NORMAL;font-weight:normal;">Medicine</text>
  <text x="584.326" y="14.110000000000014" svg_rhmargin="590.154" style="fill:#979699;font-family:DPNDJI+AkzidenzGroteskBE-Md;font-size:7.0px;font-style:NORMAL;font-weight:bold;">®</text>
  <path d="M85.039 489.493 L330.065 489.493 L330.065 490.003 L85.039 490.003 L84.812 489.89 L84.812 489.606 M443.709 35.651 L582.507 35.651 M584.0 35.651 L584.0 35.651 M440.722 35.651 L440.722 35.651 " style="fill:none;stroke:#979699;stroke-width:1.5;"/>
  <rect style="stroke:blue;stroke-width:0.3;" x="550.368" y="44.108" height="15.384" width="39.988" title="1"/>
  <text x="550.368" y="44.108" class="image" id="image.1.1" width="39" height="15">image.1.1.550_590.44_59</text>
  <text x="555.412,563.566,570.568,577.237" y="54.660999999999945" svg_rhmargin="585.238" style="fill:#ffffff;font-family:DPNDMI+HelveticaNeue-MediumExt;font-size:9.0px;font-style:NORMAL;font-weight:normal;">OPEN</text>
  <text x="335.395" y="739.622" svg_rhmargin="339.795" style="fill:#171615;font-family:DPNDMJ+AdvOTf94803d4;font-size:7.97px;font-style:NORMAL;font-weight:normal;">1</text>
 </g>
</svg>
